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Abstract
Since SARS-CoV-2 appeared in the human population, the scientific community has scram-
bled to gather as much information as possible to find good strategies for the containment
and treatment of this pandemic virus. Here, we performed a systematic review of the current
(pre)published SARS-CoV-2 literature with a focus on the evidence concerning SARS-CoV-
2 distribution in human tissues and viral shedding in body fluids. In addition, this evidence is
aligned with published ACE2 entry-receptor (single cell) expression data across the human
body to construct a viral distribution and ACE2 receptor body map. We highlight the broad
organotropism of SARS-CoV-2, as many studies identified viral components (RNA, pro-
teins) in multiple organs, including the pharynx, trachea, lungs, blood, heart, vessels, intes-
tines, brain, male genitals and kidneys. This also implicates the presence of viral
components in various body fluids such as mucus, saliva, urine, cerebrospinal fluid, semen
and breast milk. The main SARS-CoV-2 entry receptor, ACE2, is expressed at different lev-
els in multiple tissues throughout the human body, but its expression levels do not always
correspond with SARS-CoV-2 detection, indicating that there is a complex interplay
between virus and host. Together, these data shed new light on the current view of SARS-
CoV-2 pathogenesis and lay the foundation for better diagnosis and treatment of COVID-19
patients.
Author summary
Since the beginning of 2020, SARS-CoV-2 quickly spread throughout the human popula-
tion and caused a pandemic with devastating consequences at a global scale. The scientific
community is challenged to find good strategies for the containment and treatment of this
virus. In this context, an important step is charting the viral presence in the human body
to improve diagnostics, prevention or treatment.
Here, we bring together the current scientific knowledge on SARS-CoV-2 detection in
the human body and body fluids. We observe that SARS-CoV-2 impacts the human body
well beyond the lungs and shows a complex interplay with the human host that is not
always correlated with its entry receptor (ACE2) expression levels. Many studies identified
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viral components (RNA, proteins) of SARS-CoV-2 in multiple organs (pharynx, trachea,
lungs, blood, heart, vessels, intestines, brain, male genitals and kidneys) and body fluids
(mucus, saliva, urine, cerebrospinal fluid, semen and breast milk). However, besides the
lungs, researchers were only able to detect infectious virus in stool and urine in a limited
set of SARS-CoV-2 patients.
By combining these studies, our study provides an eagle’s view on the current status of
SARS-CoV-2 pathogenesis and lays the foundation for better diagnosis and treatment of
COVID-19 patients.
Introduction
Coronavirus disease (COVID-19) is considered one of the largest fast expanding pandemics
since the 1918 Spanish flu with serious consequences for global health and economy. As of July
1st 2020, the coronavirus causing COVID-19, severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), has infected more than 10 million people and caused over half a million deaths
(WHO Coronavirus Disease Dashboard, https://covid19.who.int). These numbers overshadow
the impact of the related SARS coronavirus (SARS-CoV), which caused about 8,000 infections
and 800 deaths [1]. As for SARS-CoV, SARS-CoV-2 is believed to be a derivative of an animal
coronavirus that adopted the ability of human-to-human transmission [2]. However, in con-
trast to SARS-CoV, the more contagious SARS-CoV-2 rapidly spread around the world after it
took off from a few human pilot infections in Wuhan, China.
SARS-CoV-2 spreads from one person to another through direct contact or over short dis-
tances in the air, either impacted in aerosol droplets or carried on fomites. Upon inhalation,
SARS-CoV-2 enters host respiratory cells via interaction with its entry receptor, angiotensin-
converting enzyme 2 (ACE2) and an activating receptor, a protease such as TMPRSS2 or cathep-
sin [3]. Viral replication in these cells elicits direct adverse effects on cells, but also induces local
immune cells to quickly and abundantly secrete cytokines and chemokines. In turn, an excessive
amount of immune cells are attracted to the site of infection causing a cascade of inflammatory
reactions with detrimental effects on the lungs. The current view on SARS-CoV-2 pathogenesis
focuses on these respiratory pathologies, causing symptoms such as coughing, fever, general mal-
aise, dyspnea and respiratory distress, that might eventually lead to death [4]. However, increas-
ing evidence shows that SARS-CoV-2 is not always confined to the respiratory tract, but may
also spread to other organs. Indeed, the majority of COVID-19 patients show various other
symptoms besides respiratory disorders including neurological, cardiovascular, intestinal and
kidney malfunctions [5–11]. The pathophysiological mechanisms behind the latter symptoms
are not yet fully understood. Researchers proposed viral-induced endothelial disturbances (e.g.
thrombosis, hemorrhages and edema) and defective immune responses (e.g. cytokine storm or
auto-immune reactions) as underlying reasons for multi-organ failure [5, 6]. In addition, direct
viral replication in these organs may also account for multi-organ pathologies. In this context,
the host cell entry receptor of SARS-CoV-2, ACE2, has been detected in cells from multiple tis-
sues, including the respiratory tree, cornea, esophagus, ileum, colon, gallbladder and common
bile duct tissues [12–14]. This raises the possibility for SARS-CoV-2 to engage with its receptor
at multiple organ sites upon viremia, swallowing or axonal transport and cause organ-specific
malfunctions. This replication in specific organs would enable the virus to be shed in multiple
body fluids and would augment the chances for viral transmission to new hosts.
In order to get better insight into the different organs involved in SARS-CoV-2 infection,
we performed a systematic narrative review on (pre-)published literature to determine which
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We performed a systematic literature search on SARS-CoV-2 detection studies using the
online databases PubMed (www.ncbi.nlm.nih.gov/pubmed), Web of Science (WoS, www.
webofknowledge.com) and bioRxiv/medRxiv for the time period January 1st 2020 until June
23rd 2020 (Fig 1).
The following search terms were used in Pubmed and Web of Science to construct the ini-
tial dataset of articles: ((SARS-COV2[All Fields] OR ("COVID-19"[Supplementary Concept]
OR "COVID-19"[All Fields] OR "covid19"[All Fields])) AND ("2020/01/01"[PDAT]: "2020/12/
31"[PDAT]) NOT ("review"[Publication Type] OR "review literature as topic"[MeSH Terms]
OR "review"[All Fields]) AND ("loattrfull text"[sb] AND "humans"[MeSH Terms] AND
English[lang])) AND (brain OR cerebrum OR cerebellum OR "nervous system" OR neuron�
OR spinal OR brainstem OR olfactory OR nasal OR pharyn� OR trachea OR lung OR airway
OR bronch� OR heart OR vascular OR arterial OR vena OR "blood vessel" OR "lymph node"
OR "lymph vessel" OR lymphatic OR thymus OR spleen OR "bone marrow" OR tonsils OR
blood OR oral OR mouth OR? esophagus OR stomach OR pancreas OR liver OR "gall bladder"
OR gut OR intestin� OR salivary OR saliva OR stool OR faeces OR kidney OR urethra OR ure-
ter OR bladder OR kidney OR urine OR testit OR epididym� OR prostate OR penis OR sperm
OR semen OR ovari� OR uterus OR vagina� OR placenta� OR tegument OR skin OR muscle�
OR bone OR joint OR hypothalamus OR pituitary OR thyroid OR adrenal OR reservoir OR
autopsy OR cardiovascular OR immunological OR endocrinal OR genital OR urinary OR
digestive OR respiratory). In addition, all preprint articles on SARS-CoV-2 were included in
the screening strategy.
The total set of 11700 identified articles were pooled in EndNote (version X9.3.3), dupli-
cates removed and a first filtering was performed based on following exclusion criteria: review
or editorial articles, non-English manuscripts, non-human studies and no full text available.
The remaining set of articles was manually evaluated based on their title, abstract or full text
for relevance concerning anatomical compartments, SARS-CoV-2 detection and ACE2 recep-
tor expression. During this process, the snowball method was also used to identify additional
papers that were missed by the systematic literature screening approach.
Results and discussion
Systematic literature screening
The screening resulted in 182 articles that were included in this systematic review of which 113
were retrieved from the Pubmed/WoS database and 69 from Bio/MedRxiv (Fig 1)[15–196]. In
the examined time period January 1st to June 23rd 2020, a full range of SARS-CoV-2 studies
were identified which investigated viral presence in a vast array of human tissues and body flu-
ids spread across the human body (Fig 2). Therefore, information on the presence of SARS-
CoV-2 viral fragments or particles and ACE2 receptor expression is organized by organ system
in a body map (Figs 3 and 4) and this review will further systematically address major clinical
symptoms, detection of SARS-CoV-2 and ACE2 expression levels in each organ system.
Across 182 articles, the detection of SARS-CoV-2 was performed with different methods,
with RT-qPCR-based detection of viral RNA and microscopy-based detection (electron and
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fluorescence microscopy) of viral RNA/protein being the most popular techniques. It is impor-
tant to note that these techniques do not offer definite proof for the presence of infectious
virus, therefore we summarized the level of evidence of viral presence for each organ system
(Table 1).
Fig 1. Overview of the systematic literature screening pipeline. Pubmed, Web of Science, BioRxiv and MedRxiv
were used as database sources for the time period January 1st—June 23rd 2020 and for the retrieval of SARS-CoV-2
reservoir studies.
https://doi.org/10.1371/journal.ppat.1009037.g001
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Respiratory system
The first brief reports describing pneumonia due to infection with the new coronavirus were
published in the NEJM on January 24th 2020 [15] and Nature on February 3rd 2020 [16]. In
these reports, initial identification of SARS-CoV-2 was done via sequencing and phylogenetic
analysis on lower respiratory tract and broncho-alveolar lavage (BAL) fluids collected from
patients in Wuhan from December 21st 2019 onwards. These patients had been present at the
Huanan Seafood market close to the time of symptom onset. They presented with pneumonia
of unknown etiology and showed symptoms ranging from common cold, fever, dry cough to
dyspnea. In some cases, but mostly in elderly patients, these symptoms progressed to the devel-
opment of severe acute respiratory syndrome (SARS), similar to the well-known acute respira-
tory distress syndrome (ARDS) [7]. The pathologies underlying these symptoms usually start
with alveolar damage including alveolar edema, vascular decongestion and mild inflammatory
infiltration. Later in infection, a diffuse alveolar damage in the organizing phase with reactive
type II pneumocyte hyperplasia is observed. Whether or not this will lead to lung fibrosis is
not clear yet [17]. In rare cases, excessive hypercoagulation with pulmonary embolisms can
lead to sudden death [18].
Presence of SARS-CoV-2 particles has been described in different parts of the respiratory
tract, including the nose, pharynx, trachea and lungs. SARS-CoV-2 viral RNA and/or antigens
were mainly observed in ciliated respiratory epithelial cells and type I and II pneumocytes, but
also in alveolar macrophages [19–21]. In addition, single cell RNA sequencing (scRNA-seq)
studies recovered SARS-CoV-2 viral reads from secretory and ciliated epithelial cells in BAL
[22] and bronchiolar protected specimen brushes (PSB) [23] from COVID-19 patients. SARS-
CoV-2 viral transcripts were also detected in macrophages and neutrophils obtained from
BAL, albeit at low levels [22, 23]. Whether this results from direct infection or phagocytosis of
infected cells or viral particles remains to be elucidated.
To gain a better understanding of the epithelial subtypes targeted by the virus, Ravindra
et al. [24] performed scRNA-seq analysis on in vitro infected human bronchial epithelial cells.
This study pointed to the ciliated epithelial cells as the major initial target of infection and this
Fig 2. Overview of organ systems studied in SARS-CoV-2 human reservoir studies for the time period January 1st
to June 23rd 2020. Next to the widespread use of nasopharyngeal or oropharyngeal swabs (not included in the graph),
a full range of SARS-CoV-2 reservoir studies were identified which examined a vast array of human tissues and body
fluids.
https://doi.org/10.1371/journal.ppat.1009037.g002
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was confirmed by EM analysis. At later stages of infection, virus was also detected in other epi-
thelial subsets, including basal, club and BC/club cells. Surprisingly, this study pointed out that
ACE2 expression poorly correlated with SARS-CoV-2 detection on a per cell basis. ACE2 was
mainly expressed in ciliated cells, club cells and to a lesser extent type II pneumocytes [24, 25].
In this context, ACE2 expression is seemingly higher in the upper airways than in lower air-
ways, while the latter are more affected by SARS-CoV-2 replication [26].
Viral replication in the respiratory tract results in viral shedding in mucus, as evidenced by
multiple studies showing viral RNA in nasal and throat swabs. These swabs remain positive for
up to 15 days post infection, indicating that viral particles or fragments of viral RNA are still
present [27]. Some researchers even demonstrate viral shedding up to 60 days after onset of
symptoms [28–30]. Such prolonged viral RNA shedding was mainly observed in elderly
patients [31]. Still, relapse involving aggravation of pulmonary dysfunction has only rarely
been reported [32]. Moreover, in immunocompromised patients persistent viral shedding and
positive PCR with threshold Ct’s of 30 have been reported [33].
Although viral RNA is routinely detected by RT-qPCR from both upper and lower respira-
tory tract samples and in particular cases can remain detectable up to 2 months after the onset
Fig 3. Overview of SARS-CoV-2 presence in the human body. Gradient color (purple) indicates low to high evidence for SARS-CoV-2 detection in this
organ, tissue or body fluid. Highest expression was found in upper airways, lungs and oral cavity together with the gastrointestinal tract and urinary system.
This figure was created with BioRender.com.
https://doi.org/10.1371/journal.ppat.1009037.g003
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of symptoms, this does not prove that replication is ongoing in the sample sites and that
patients are still infectious. Several studies have isolated infectious virus, that can be propa-
gated in vitro, both from upper and lower respiratory tract samples [34–40]. Longitudinal
studies indicate that successful viral culture is mostly established from samples obtained within
9 days of onset of symptoms [34, 36, 37]. Interestingly, several studies observed a clear correla-
tion between the viral load as assessed by RT-qPCR and the infectivity of the sample, although
the reported threshold Ct values that would permit infectivity range from < 24 to< 33 [34, 35,
38], which hampers the use of RT-qPCR as a surrogate diagnostic to predict patient infectivity.
Also, viral loads detected in asymptomatic or minimal symptomatic patients were similar
to those of symptomatic patients, hinting towards the transmission potential of asymptom-
atic patients. This is confirmed in a prevalence study conducted in a nursing home, showing
that viral loads were not different between symptomatic, asymptomatic and presymptom-
atic residents and that viable virus could be isolated from 6 days prior to 9 days past the
onset of symptoms [37]. In conclusion, the respiratory tract is the major site of infection,
and although virus can be detected for up to 2 months post infection, most studies indicate
infectivity is highest in the two weeks post-infection.
Fig 4. Overview of ACE2 expression levels in the human body. Gradient color (orange) indicates low to high evidence for ACE2 expression in this tissue or
body fluid. Highest expression was detected in the oral cavity, gastrointestinal tract and the male reproductive system. This figure was created with BioRender.
com.
https://doi.org/10.1371/journal.ppat.1009037.g004
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Table 1. Overview of SARS-CoV-2 detection in the human body, organized per organ system. Organ systems are shown on the left, followed by type of virus detection
and amount of positive samples.
RT-qPCR (viral RNA) Electron/Fluorescence Microscopy/
Immunohistochemistry (viral RNA or protein)





used as diagnostic COVID-19 test� N.D. Virus can be isolated out of 17–100% of
qRT-PCR-positive samples [34–40]
Sputum used as diagnostic COVID-19 test� N.D. Virus can be isolated out of 30–100% of
qRT-PCR-positive samples [35, 36, 38–40]
BAL used as diagnostic COVID-19 test� N.D. N.D.
Trachea 12/12 [19] tracheal epithelial cells (EM) [19], RNA-ISH [21] N.D.
Lung 12/12 [19] type I pneumocytes (EM) [17, 19], RNA-ISH [21] N.D.
type II pneumocytes (EM [17], IHC [20], RNA-ISH
[21]
N.D.
alveolar macrophages (EM) [17]
Cardiovascular system
Heart biopsies 12/15 [19, 42] interstitial cells of the myocardium [43] N.D.
Blood vessels N.D. blood vessel organoids (FM) [44] blood vessel organoids can productively be
infected [44]
Immune system
Immune cells RNA seq: rare reads [50, 52] macrophages [16], virus like particles in CD4+ T
cells [53]
N.D.
Blood and plasma 52/384 [52–55] N.D. N.D.
Immunesystem-related
biopsies
spleen and lymph node [23, 42] N.D. N.D.
Digestive system
Stool 504/874 [9, 30, 55, 60–90] N.D. two reports isolated infectious virus [77,
79]
Rectal swabs 22/77 [55, 72, 86, 91, 92] N.D. N.D.
Saliva 683/758 [89, 94–106] N.D. N.D.
Gut biopsies 2 severe patients: esophagus,
stomach, duodenum and rectum
[9]
gastric, duodenal and rectal epithelia (FM) [79] N.D.
large intestines [19] large intestines lumen (EM) [19] N.D.
Urinary system
Urine 23/467 [36, 39, 68, 72, 77, 87–89,
92, 132–134, 142]
N.D. one report isolated infectious virus [135]
Kidney biopsies 3/3 severe patients [19] tubular epithelium, podocytes and endothelium
(EM, IHC) [19, 125–127]
kidney organoid (FM) [44] kidney organoids can productively be
infected [44]
Reproductive system
Semen 6/85 [136, 137, 141, 142] N.D. N.D.
Prostate secretions 0/23 [143] N.D. N.D.
Testis biopsies 0/1 [137] spermatogenic cells, Sertoli cells and Leydig cells
(IHC) [20]
N.D.
Vaginal swabs 0/35 [144] N.D. N.D.
Placental swabs, cord swabs
and/or amniotic fluid
0/12 [148–150] N.D. N.D.
Breast milk 5/42 [156–159] N.D. 0/9 [159]
Nervous system
Cerebrospinal fluid 4/18 [160, 161, 167–172, 174] N.D. N.D.
Brain biopsies 8/34 [19, 173, 174] N.D. N.D.
(Continued)
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Cardiovascular system
The majority of humans that test positive for SARS-CoV-2 infection do not develop fulminant
cardiovascular disease during the acute infection. However, about 20% of the patients admitted
to intensive care units develop acute cardiac injury during the course of infection [7, 8].
Whether SARS-CoV-2 facilitates the reported cardiac injuries via direct infection or by trigger-
ing inappropriate immune activation is not known. The study of Remmelink et al. [41] reports
quantification of viral RNA in the heart in post-mortem patient samples, but did not observe
specific viral organ injuries [41]. Two other studies used electron microscopy to detect virus,
and of these studies one was able to detect viral RNA, but not viral particles, in the heart [19].
The other study found virus particles in cytopathic, structurally damaged interstitial cells, but
not in cardiac myocytes [42]. It is therefore more likely that cardiac injury in patients occurs
by inflammation rather than direct infection. Interestingly, one autopsy series of three
COVID-19 patients demonstrated endothelitis in vascular beds of different organs and
detected viral inclusions via EM in kidney endothelial cells of one patient [43]. Susceptibility
of endothelial cells to SARS-CoV-2 infection is furthermore supported by in vitro infection
studies with blood vessel organoids [44] and pluripotent stem cell-derived cardiomyocytes. In
line with this, relatively high expression of ACE2 in heart tissue supports the potential of direct
infection [25, 45]. Furthermore, increased expression of ACE2 in patients with heart failure
was observed, indicating a potential risk group [46–49]. Although in vitro infection studies
and expression of ACE2 are suggestive for active infection of the heart, it remains unclear
whether this results into cardiac injury as post-mortem studies are inconclusive on the matter.
Therefore further research on post-mortem samples or biopsies taken during infection are
required to verify if the heart and vasculature could potentially serve as a site of prolonged
virus persistence.
Immune system
Even though immune responses during infection with SARS-CoV-2 can lead to severe compli-
cations, no viral replication is observed in immune cells from patients. Interestingly, there are
rare reports of viral RNA detection in RNA-seq data from peripheral blood mononuclear cells
(PBMCs) [50–52]. In addition, post-mortem studies showed presence of SARS-CoV-2 RNA
and antigens in draining lymph nodes and spleen, predominantly in macrophages [19, 20].
One in vitro study used virus isolated from patients to test replication kinetics in PBMCs but
could not find evidence of SARS-CoV-2 propagation in this heterogeneous population of cells,
Table 1. (Continued)
RT-qPCR (viral RNA) Electron/Fluorescence Microscopy/
Immunohistochemistry (viral RNA or protein)
Culturing virus out of (liquid) biopsies
(infectious particles)
Sensory system: Eye
Tear samples 1/94 [182, 188, 189] N.D. N.D.
Conjunctival swabs 8/222 [182–188] N.D. N.D.
Skin and adipose tissue
Skin N.D. N.D. N.D.
Adipose N.D. N.D. N.D.
RT-qPCR; reverse transcriptase quantitative polymerase chain reaction, EM; electron microscopy, FM; fluorescence microscopy, IHC; immunohistochemistry, ISH; in
situ hybridization, N.D.; not determined. � RT-qPCR data on nasopharyngeal and oropharyngeal swabs, sputum and BAL are not mentioned, as these often function as
diagnostic marker for further analyses. Thus, a definite analysis of the exact amount of positive samples is difficult to assess.
https://doi.org/10.1371/journal.ppat.1009037.t001
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despite the observation of viral-like particles in primary CD4+ T cells by electron microscopy
[53]. Detection of viral RNA has been observed in plasma of severe patients, but it remains
questionable whether this RNA originates from actual virus particles or merely represents the
potentially infectious viral genome [54, 55]. Therefore, detecting RNA in plasma does not
directly translate into the presence of infectious particles. In any case, detection of SARS-CoV-
2 in multiple organs indicates that infectious virus/RNA is circulating in at least part of the
COVID-19 patients. Furthermore, using RNA sequencing data it was found that immune cells
barely express the ACE2 receptor required for viral entry nor any other of the major entry pro-
teins [50, 56, 57]. These studies provide the ground for the hypothesis that virus detected in
immune cells results from cellular entry by phagocytosis. Since no viral replication was
observed thus far in immune cells, it seems that immune cells do not function as a functional
reservoir for SARS-CoV-2.
Digestive system
Gastro-intestinal (GI) tract symptoms are reported in approximately 10–15% of COVID-19
cases and typically include diarrhea and to a lesser extent nausea, vomiting or abdominal pain
[9, 58, 59]. Patients with only GI symptoms were more likely to be diagnosed later than
patients with additional respiratory complaints and are more likely to be positive for SARS-
CoV-2 RNA in fecal samples [60].
Stool samples from 874 patients across 34 studies were examined of which 504 (57.67%)
resulted in a positive RT-qPCR for COVID-19 irrespective of disease severity [9, 30, 55, 60–
90]. Five studies also included rectal swabs of 77 patients of which 22 tested positive (28.5%)
[55, 72, 86, 91, 92]. Stool samples remained positive well after NP swabs returned negative
with a range of 1–47 days, indicating longer and extended viral shedding via this route. Also,
infectious virus could be isolated from stool samples in at least two reports, indicating the pos-
sibility of feco-oral transmission but no reports have shown direct evidence of this occurring
[77, 79]. Indeed, stability of SARS-CoV-2 was tested in faeces in vitro and was shown to be sta-
ble and infectious for several hours [93].
Saliva samples from 758 confirmed COVID-19 patients across fourteen studies yielded high
positive SARS-CoV-2 detection results which are often in concordance with matched NP
swabs (657/758 patients, 86.7%)[89, 94–106]; however, in a limited set of cases (26 patients)
saliva samples were reported positive with a negative NP swab [95, 98, 99, 106]. SARS-CoV-2
could be detected in saliva 10–37 days after onset of symptoms [97, 100, 102] and in two-out-
of-three studies was shown to yield higher viral load titers than NP swabs [103, 104, 107]. In
addition, SARS-CoV-2 viral particles were shown to be stable in artificial saliva up to 90 min-
utes [108, 109], further confirming this as a major viral shedding route.
From immunofluorescence and scRNA-seq studies it became apparent that ACE2 expres-
sion is high in epithelial cells across the entire gastro-intestinal tract including the oral mucosa
of the tongue and enterocytes from the ileum and colon [110–113]. As described above, SARS-
CoV-2 has already extensively been recovered from saliva samples and oral swabs. However,
whether this results from actual viral replication in the oral (tongue) mucosa and/or salivary
glands or is merely a spill-over from the pharynx remains unclear. Nonetheless, the apparent
loss of taste in certain COVID-19 patients additionally suggests that SARS-CoV-2 replicates in
cells aligning the tongue [114, 115]. Likewise, there is a limited number of studies performed
which actually examine viral presence in GI tissues. One study by Lin et al. performed endo-
scopic sampling in 6 patients of which 2 severe patients tested positive for viral RNA measured
by RT-qPCR from the esophagus, stomach, duodenum and rectum [9]. Only 1 out of 4 non-
severe cases tested positive in the duodenum. Xiao et al. confirmed these findings by
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visualizing SARS-CoV-2 viral capsid via intracellular staining of gastric, duodenal, and rectal
epithelia in GI tissues [79]. One post-mortem study by Bradley et al. visualized viral particles
in the lumen of the large intestines via electron microscopy and found borderline positive RT-
qPCR results from tissue biopsies in the large intestines (Ct value between 37–40), but not in
the small intestine [19]. Finally, Lamers et al. demonstrated that enterocytes of ex vivo orga-
noids are infectable with SARS-CoV-2 and that the virus can replicate, indicating that these
cells are permissive for SARS-CoV-2 infection [116].
Overall, these findings indicate the broad presence of SARS-CoV-2 RNA or viral fragments
in the GI tract with a preference for saliva and stool. Indeed, live virus could be isolated from
stool, although from a limited set of patients. Therefore, further studies are needed to map the
actual viral presence, especially in gut tissues.
Recurring clinical features of the other solid organs of the digestive tract (liver, gallbladder,
pancreas) mainly include liver injury with abnormal liver tests in 35–56% of the COVID-19
patients for aspartate aminotransferase (AST), alanine aminotransferase (ALT) and bilirubin
which is probably due to the immune cascade in the body [117, 118]. In addition, there is a sin-
gle case report indicating a rare onset of SARS-CoV-2-induced pancreatitis in two patients
and one cohort study describing pancreatic injury in 10% of COVID-19 patients, indicated by
elevated amylase (13/121 patients) or lipase levels (12/121 patients), of which three developed
pancreatitis. The limited number of reports indicate that pancreatic injury is often overlooked,
hence there is in sufficient data on the widespread presence of this illness [119, 120]. To date,
there are no reports on the possible presence of SARS-CoV-2 in these organs, although ACE2
expression can be high and is found in liver cholangiocytes, TROP2+ liver progenitor cells,
gall bladder epithelium, pancreatic exocrine glands and islets [49, 121, 122]. Therefore, tissue
biopsies with immunohistochemical viral staining or RT-qPCR for viral RNA (i.e. from post-
mortem studies) could deliver necessary information, but so far robust data is lacking to con-
clude that solid organs of the digestive tract play a major role in SARS-CoV-2 infection.
Urinary system
Routine urinalysis of COVID-19 patients shows abnormalities such as proteinuria, hematuria
and leukocyturia in up to 75% of the cases [123, 124]. Further, up to 27% of hospitalized
COVID-19 patients even develops acute renal failure, especially elderly with comorbidities
such as hypertension and heart failure [10, 125]. Tubule degeneration, necrosis and to a lesser
extent renal thrombotic micro-angiopathy typically account for acute renal failure. These
observations indicate that the human kidney may be a target for SARS-CoV-2. Indeed, viral
RNA, proteins and particles have been found in kidney tubular epithelium, podocytes and to a
lesser extent in kidney endothelium of deceased COVID-19 patients [19, 44, 125–127]. This
pattern is consistent with ACE2 distribution, as ACE2 is highly expressed onto proximal
tubule cells [128–131]. Of note, SARS-CoV-2 was also able to infect human kidney organoids
in vitro [44]. Despite reports of SARS-CoV-2 presence in the kidney, viral shedding in urine is
rather rare, as viral RNA could only be detected in urine samples of 3–4% of COVID-19
patients [36, 39, 68, 72, 77, 87–89, 92, 132–134]. However, one study was able to isolate infec-
tious virus particles out of positive urine samples [135]. Further, viral shedding in urine may
continue even after respiratory shedding has ceased, indicating that the human urinary tract
may act as a long-term source of SARS-CoV-2 detection[68].
Reproductive system
Except for few reports on testicular pain, fertility problems or other genital tract-related disor-
ders due to COVID-19 have not been described to date [136]. Nonetheless, SARS-CoV-2
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proteins have been found inside spermatogenic cells, supporting Sertoli cells and testosterone-
producing Leydig cells of a COVID-19 patient [20]. These virus-positive testes did not show
any additional histological abnormalities. In contrast, the testes of another COVID-19 patient
did not show any presence of SARS-CoV-2 RNA [137]. Interestingly, the spermatocytes, Ser-
toli and Leydig cells express a high level of ACE2, compared to other cells in the human body
[138–140]. In line with SARS-CoV-2 protein detection in testes, one study detected SARS-
CoV-2 RNA in 6 out of 38 semen samples from COVID-19 patients. From the positive samples
4 were collected at the acute stage of infection, whereas 2 were obtained from recovering
patients [141]. Still, in four other studies all semen and prostate secretions of 47 and 23, respec-
tively, COVID-19 patients tested negative for SARS-CoV-2 RNA [136, 137, 142, 143]. Presence
of SARS-CoV-2 in the female reproductive tract has not been described so far. A number of
vaginal swabs of COVID-19 patients also tested negative for viral RNA [144]. Unlike male
gonads, female reproductive organs do not express ACE2 at the bulk level [25, 140]. These
data indicate the male, rather than the female, genital tract may be susceptible and permissive
for SARS-CoV-2 infection. Still, further studies are necessary to confirm this assumption.
Although only one out of five studies detected viral RNA in semen, possible sexual transmis-
sion of SARS-CoV-2 and the role of the male genital tract in SARS-CoV-2 infection needs fur-
ther study.
Regarding SARS-CoV-2-positive mothers, despite vascular abnormalities observed in up to
50% of examined placentas, there is no clear evidence of vertical virus transmission to infants
[145, 146]. In line with the absence of virus in placenta, amniotic fluid or cord blood, the
human placenta does not express high levels of ACE2 [147–151]. In some cases, neonates can
still become infected by SARS-CoV-2 after birth through horizontal transmission [152–155].
In addition to respiratory droplets, breastfeeding has been suggested as a mechanism of SARS-
CoV-2 transmission, as this has been reported for other RNA viruses, such as HIV. Data are
limited, but viral RNA has been identified in breast milk of 5 out of 42 COVID-19-positive
breastfeeding mothers so far [156–159]. Although still anecdotal, the most convincing evi-
dence for the possible occurrence of SARS-CoV-2 in milk is provided by a study of milk sam-
ples from two SARS-CoV-2-positive breastfeeding mothers, demonstrating SARS-CoV-2
RNA in milk samples from one mother for four consecutive days [157]. Still, it was impossible
to recover infectious virus from RNA-positive milk samples, suggesting that breastmilk itself is
unlikely to pass on SARS-CoV-2 to infants [159]. However, more evidence is needed to con-
clude on the definite role of breastfeeding in SARS-CoV-2 transmission.
Nervous system
The majority of COVID-19 patients (up to 78%) show neurological symptoms ranging from
headache, loss of smell (anosmia) and taste (ageusia), imbalance, impaired consciousness,
delirium and paresthesia to extremity paralysis and convulsions [11, 114, 115, 160–163]. Severe
neurological symptoms can mostly be accounted to abnormalities located in the brain(stem)
and spine such as edema, hemorrhages and thrombotic events with or without stroke, demye-
lination and encephalomyelitis [163–166]. This has urged many researchers to look closer into
the nervous system of COVID-19 patients. In COVID-19 cases with severe neurological symp-
toms, viral RNA has been identified in 4 out of 8 cerebrospinal fluid (CSF) samples [160, 161,
167–172]. Moreover, one autopsy study found traces of viral RNA via RT-qPCR in the brain of
8 out of 22 deceased COVID-19 patients [173]. Yet, two other studies failed to identify virus
particles or RNA in brain autopsies and CSF analysis of 12 and 10, respectively, deceased
COVID-19 patients [19, 174]. Therefore, it remains unclear whether severe neurological mani-
festations are triggered by direct viral-induced damage or virus-induced endothelial and/or
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cytokine disturbances. Nonetheless, ACE2 is expressed in both neuronal and non-neuronal
cell types in the human central nervous system, especially in the spinal cord, dorsal root gangla,
brainstem substantia nigra, choroid plexus, hypothalamus, hippocampus, middle temporal
gyrus and posterior cingulate cortex [175, 176]. This hints towards the possibility of SARS-
CoV-2 invasion of the central nervous system. In contrast to severe neurological symptoms,
ageusia and anosmia are often devoid of any obvious lesions [114, 115]. Direct viral damage to
the olfactory and gustatory receptors or neurons has been proposed as mechanism of sensori-
neural olfactory loss, but the absence or presence of SARS-CoV-2 inside olfactory epithelial or
neuronal cells has not been described so far. This is probably related to technical difficulties
during COVID-19 patient autopsy, such as inaccessibility of the olfactory bulb and epithelium
without the use of electric saws to cut into the skull. This generates potentially virus-loaded
aerosols, necessitating the use of additional, sometimes difficult to take, precautions. Interest-
ingly, non-neuronal cells rather than neuronal cells residing in the olfactory epithelium and
bulb express ACE2 and TMPRSS2 [175, 177–179]. This indicates that SARS-CoV-2 replication
in the olfactory epithelium might induce anosmia through perturbation of supporting cells,
rather than direct neuronal infection. Together, these findings indicate that SARS-CoV-2 is
able to reach the nervous system.
Sensory system: Eye
Ocular symptoms remain rare in COVID-19 patients but reported symptoms in hospitalized
patients include: dry eyes, blurred vision, foreign body sensation and conjunctivitis with con-
junctival congestion. However, there remains a debate whether this is directly caused by the
virus [180, 181]. As SARS-CoV was readily detectable in tears, Xia et al. investigated the viral
presence of SARS-CoV-2 RNA in tears and conjunctival swabs from 30 COVID-19 patients
who were sampled twice longitudinally [182]. Only one patient showed a positive PCR test on
tears and ocular surface swabs with onset of conjunctivitis and conjunctival congestion. How-
ever, the virus could not be isolated or cultured in vitro. This was also reported by Xie et al.,
Kumar et al., Wu et al., and Zhou et al. who detected SARS-CoV-2 RNA in ocular surface
swabs or conjunctival secretions of 2/33, 1/45, 2/28 and 1/63 patients, respectively [183–186].
One case report performed longitudinal sampling in a single patient and confirmed a positive
signal of conjunctival swabs up to 17 days after onset of disease [187]. In contrast, Seah et al.
and Xu et al. could not replicate these findings and did not detect SARS-CoV-2 in 64 tear sam-
ples from 34 patients [188] or in ocular surface swabs from 22 patients [189]. Reports on
ACE2 expression find a limited expression at the retina and specifically in the retinal epithe-
lium [180]. Moreover, ACE2 and TMPRSS2 are co-expressed in corneal and conjunctival epi-
thelial cells according to scRNA-seq and immunohistochemical analyses, identifying the
ocular surface as a potential viral entry site [190, 191]. Therefore, infection could occur via
droplets entering the eye and travel via the nasolacrimal canal to the respiratory tract.
In total across eight studies examining ocular presence of SARS-CoV-2 RNA, 1/94 patients
tested positive for tear or conjunctival secretion samples and 8/222 ocular surface swabs. These
low numbers can be influenced by the time of sampling and by the onset of conjunctivitis but
show that ocular fluids can contain SARS-CoV-2 viral fragments RNA. However, no reports
state that SARS-CoV-2 virus could be isolated from ocular fluids at present.
Skin and adipose tissue
The documentation and available papers surrounding SARS-CoV-2 in relation to adipose and
skin tissue is very limited. About 20% of patients present or develop cutaneous manifestations
at or during the onset of COVID-19, but not related to severity of infection. These patients
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presented themselves with erythema, and a positive diagnostic test for SARS-CoV-2 [192–
194]. No tests on skin tissue have thus far been performed, however, and therefore it cannot be
excluded as an underlying illness or as a manifestation of the immune response. Remarkably,
ACE2 receptor is expressed in skin biopsies, and patients with rash and skin lesions have
increased expression of TMPRSS2 (a co-receptor of SARS-CoV-2] [57]. Therefore, rash could
also be the symptom of infection leading to lesions, but this needs to be confirmed and further
investigated. In adipose tissue thus far no virus has been detected. However, the paper of van
der Poort et al. (2020) found that patients that have an increased Body Mass Index (BMI) also
have increased leptin levels in serum, which they hypothesize could correlate with severity of
the infection [195, 196]. Interestingly, increased expression of the ACE2 receptor in the lung
epithelia are positively correlated with obesity, indicating that obese individuals might be at
higher risk for SARS-CoV-2 infection [195, 196]. In conclusion, there is no robust evidence to
either demonstrate or exclude that skin and adipose tissue harbor SARS-CoV-2 viral particles.
Conclusion
SARS-CoV-2 affects many organs throughout the human body
The first studies on SARS-CoV-2 tropism and pathogenesis focused on the lungs, as these were
“the viral ground zero”. However, it quickly became clear that SARS-CoV-2 also attacks other
organ systems, either by direct viral infection or through indirect effects of the immune response.
Our systematic review showed that traces of the virus have been found in multiple organs
throughout the body, including the pharynx, trachea, lungs, blood, heart, vessels, intestines, male
genitals, brain and kidneys. In line with this, SARS-CoV-2 components were also detected in a
variety of body fluids such as mucus, saliva, urine, semen, faeces, cerebrospinal fluid and breast
milk. Of note, although SARS-CoV-2 RNA has been detected in plasma of patients with severe
disease [54, 55, 197], no study has as yet demonstrated the presence of infectious virus in blood.
It therefore remains to be demonstrated that SARS-CoV-2 might infect organ systems by gaining
access to the bloodstream. Although highly speculative at the moment, SARS-CoV-2 might cause
a persistent chronic infection in certain individuals. In these patients, certain sites might act as a
“viral reservoir”, in which the virus can persist for prolonged periods accompanied by recurrent
viral shedding. This phenomenon is not new for RNA viruses, as this has already been described
in Ebola virus survivors [198]. SARS-CoV-2 persistence and recurrent shedding has already been
demonstrated in the respiratory tract [33], but also sites of attenuated immunity such as the testis,
eye and brain might potentially preserve the virus for longer times. Nonetheless, this hypothesis
should be treated with caution, as the number of studies showing actual infectious virus particles
in different organs remains limited so far.
ACE2 expression and SARS-CoV-2 infectivity: not a perfect match
Given the role of ACE2 as the main cellular entry receptor for SARS-CoV-2 in vivo, ample
studies have attempted to map ACE2 expression to obtain insight into tissues or cell types that
are in theory susceptible to SARS-CoV-2 infection. Interestingly, presence of SARS-CoV-2
components in different tissues does not always correlate with steady-state ACE2 expression
levels. For instance, high viral loads are retrieved from the lungs, which generally show rather
low ACE2 expression levels. In the gastrointestinal tract, viral loads peak in the colon, while
ACE2 expression is higher in the small intestine. Thus, it seems that there is not always a per-
fect match between ACE2 expression and SARS-CoV-2 detection. A plausible explanation for
this apparent mismatch might be the fact that few ACE2 molecules might suffice to cause a
productive SARS-CoV-2 infection. Alternatively, cell type heterogeneity in ACE2 expression
within a given tissue can also contribute as well as a discordance between ACE2 mRNA
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expression and cell-surface ACE2 expression. Further in depth analysis of cell-surface ACE2
protein expression is however required to confirm these hypotheses. Of note, most evidence
on ACE2 expression in different tissues is based on a steady-state situation in healthy individu-
als. In diseased individuals, expression levels of ACE2 might differ. Indeed, several comorbidi-
ties associated with severity of COVID-19 disease such as smoking, diabetes, COPD, obesity
and hypertension are characterized by elevated levels of ACE2 expression in the respiratory
tract [199–201]. However, whether severe progression of COVID-19 in these patients is a
direct consequence of abundant ACE2 expression and thus increased susceptibility to SARS-
CoV-2, or is merely the result from underlying health issues in these individuals (e.g. immuno-
suppression) is unclear. Counterintuitively, ACE2 receptor abundance in plasma is high in
children, who often show minor symptoms upon SARS-CoV-2 infection, while it goes down
in the elderly, who are at greater risk of severe illness [202, 203]. This apparent paradox might
be explained by the discrepancy between membrane-bound and soluble ACE2 molecules.
While the membrane-bound form acts as host cell receptor for SARS-CoV-2, soluble ACE2
may neutralize free virions by shielding the viral binding protein spike (S) [204]. In this way,
elevated soluble ACE2 levels in children may help them to contain the virus. Thus, it is clear
that researchers only discovered the “tip of the iceberg” in SARS-CoV-2 pathogenesis so far.
Limitations
As described in this review, only a limited set of studies succeeded in isolating and culturing
SARS-CoV-2 viral particles out of a biopsy that were also capable of reinfecting target cells in
vitro, providing definite proof of replication-competent viral presence of SARS-CoV-2. Impor-
tantly, this “golden standard”evidence is currently only available for respiratory and gastro-
intestinal tract samples and it remains to be established whether the “viral signal” detected in
other organs systems via RT-qPCR or microscopy derives from genuine infective viral particles
[205]. For instance, in electron microscopy, viral particles might be mistakenly identified over
other endogenous vesicles or endocytic bodies [206] and a (borderline) positive signal in RT-
qPCR could be due to leftover viral RNA fragments rather than replication-competent virus.
Indeed, as virus is phagocytosed by immune cells and these cells can travel throughout the
body and invade different tissues, weak signals detected via RT-qPCR might derive from
immune cells that phagocytosed virus at distant locations.
An important limitation of this study is that information on viral load/ACE2 expression in
patient samples is biased towards sample types that are easily accessible such as body fluids or
blood cells. For instance, although scRNAseq studies could yield interesting information on
SARS-CoV-2-targeted cell types, the epithelial cells, which constitute the major target of
SARS-CoV-2 according to the available evidence, are underrepresented in respiratory samples
obtained from patients. Most information on less accessible tissues/cell types therefore derives
from autopsy studies, which are biased towards analyses of the subset of patients with critical
COVID-19 disease and also represents an endpoint analysis. These limitations could be
addressed with an appropriate animal model, replicating the pathogenesis of human COVID-
19 [207]. However, although the mild COVID-19 phenotype and viral replication in the respi-
ratory tract can be mimicked in non-human primates, hamsters, ferrets and cats, none of these
animals features the cytokine storm and coagulopathy that characterizes severe COVID-19 in
humans [208]. Therefore, this review primarily focused on SARS-CoV-2 studies in the context
of humans.
Finally, difficulties inherent to the heterogeneous SARS-CoV-2 research are the variability
in study design, patient numbers and characteristics, sampling timing and testing procedures.
Furthermore, the included preprint articles should be treated with caution because no strict
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peer review process was performed. This systematic review focused on research articles avail-
able in English and on studies reporting human data.
These limitations should be considered while interpreting these data.
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